Piper Sandler analyst Matt O’Brien previously had questioned whether more inspection notices related to Medtronic’s (MDT) Northridge diabetes facility would mean that the 780G would be delayed further, stating that if that were to be the case it "could be some well-received news" for Tandem Diabetes (TNDM) and Insulet (PODD). Shares of Tandem are down over 5% to $36.88 in afternoon trading after the FDA announced it has approved the MiniMed 780G System for modifications to the SmartGuard Technology and for expanding the indications for use to include the Guardian 4 Sensor, while shares of Insulet are down 1% to $316.65.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on TNDM:
- Tandem Diabetes Care announces publication of meta-analysis of Control-IQ trials
- Piper wonders if Medtronic’s 780G will be delayed further by FDA inspections
- Tandem Diabetes initiated with a Neutral at UBS
- Tandem Diabetes initiated with a Neutral at UBS
- Tandem Diabetes announces NEJM publication of study on t:slim X2 insulin pump